Non-small cell lung cancer
Conditions
Interventions
Control group:Placebo + standard chemotherapy regimen after surgery for non-small cell lung cancer
Experimental group:Qizhen capsule + standard chemotherapy regimen after surgery for non-small cell lung cancer
Sponsors
Beijing Hospital of Traditional Chinese Medicine Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients after radical surgery for stage Ib-III non-small cell lung cancer (2) Mutations in driver genes such as EGFR/ALK are negative or unknown (3) The first adjuvant chemotherapy is planned to be performed within 6 weeks after surgery (4) ECOG score 0-2 points (5) Aged 18-75 years old the bone marrow and important organ functions meet chemotherapy requirements (6) Good compliance and sign an informed consent letter
Exclusion criteria
Exclusion criteria: (1) Patients without clear pathological diagnosis (2) Patients with recurrence and metastasis before the first adjuvant treatment (3) Patients suffering from other primary malignant tumors at the same time (4) Pregnant and breastfeeding women or those with serious diseases of the heart lung liver kidney blood etc. the researchers believe that it is not suitable for enrollment. (5) Patients who are known to be allergic to research medication (6) Patients undergoing other drug trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year Disease-Free Survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-Year/2-Year Overall Survival Rate(1-year/2-year OS rate);Median Overall Survival(mOS);Chemotherapy adverse reactions;Median Disease - Free Survival(mDFS);T lymphocyte subsets and cytokines;quality of life;1-Year Disease-Free Survival Rate;syndromes\tongue and pulse conditions\symptoms of Traditional Chinese Medicine; | — |
Countries
China
Contacts
Public ContactXiaomin Wang
Beijing Hospital of Traditional Chinese Medicine Capital Medical University
Outcome results
None listed